CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma

Starting soon · Phase 1/Phase 2

Conditions studied: Classical Hodgkin Lymphoma

In brief

Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.

Key facts

Study ID

NCT06617286

Run by

New York Medical College

People needed

21

Starts

2026-12-01

Expected to finish

2040-12-31

Last updated by the study team

2026-04-15

Who can join

Age: 6 and older, up to 29. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age between ≥ 6 and ≤ 29.99 years at the time of consent.
• Lansky OR Karnofsky score of ≥ 60% (see Appendix VI)
• Disease Status: Confirmed diagnosis of CD30+ classical Hodgkin Lymphoma and meets eligibility to undergo ASCT. Must meet one of the following:
• Induction failure Progressive disease Disease relapse (1st, 2nd or 3rd)
• Confirmatory re-biopsy of relapse/refractory/persistent CD30+ cHL prior to study entry.
• Risk Factors: Patient must meet 2 or more of the established risk factors:
• Performance score (Karnofsky/Lansky) <;90% Time from diagnosis to first relapse of <1 year Extra nodal involvement at the time of relapse/progression High baseline metabolic tumor volume (MTV, >60mL) by 18F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) Chemo resistant disease (Deauville 4-5) after the first re-induction

You may not qualify if…

• not meeting the inclusion criteria

Where it is running

• New York Medical College — Valhalla, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.